|Depression||Tablets||10 and 20 mg|
|Buprenorphine||Opioid dependence||0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films|
|Eslicarbazepine||Epilepsy||Tablets||400 and 1200 mg|
|Fluoxetine||Depression||Tablets||10 and 20 mg|
|Lamotrigine||Lamotrigine||XR tablets||25/ 50/ 100/ 200 & 300 mg|
|Levetiracetam||Epilepsy||XR tablets||1; 1,5; 2 and 3 g XR coated minitablets|
|Pyridostigmine||Myasthenia gravis||Film-coated tablets||60 mg|
|Pyridostigminie||Myasthenia gravis||XR tablets||180 mg|
|Quetiapine *||Psychosis, schizophrenia, bipolar disoder||Orodispersable tablets||25 and 50 mg|
|Rotigotine||Parkinson disease & restless legs||Patches||1, 2, 3, 4, 6 and 8 mg/24h|
[*] Differentiated product
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.